EUCTR2018-001904-12-GB进行中（未招募）1 期
Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH) - Desmopressin for treatment of stroke patients on antiplatelet therapy
niversity of Nottingham0 个研究点目标入组 50 人开始时间: 2019年11月12日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Adults (>16 years)
- •Confirmed intracerebral haemorrhage on imaging
- •Less than 12 hours from onset of symptoms [or from when last seen healthy]
- •Prescribed and thought to be taking a daily oral antiplatelet drug in the preceding seven days (cyclooxygenase inhibitors, phosphodiesterase inhibitors or P2Y12 inhibitors)
- •Signed consent (patient/personal/professional representative)
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 2
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 13
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 35
排除标准
- •Aneurysmal subarachnoid haemorrhage known at time of enrolment
- •Haemorrhage known to be due to transformation of infarction
- •Haemorrhage known to be due to thrombolytic drug
- •Haemorrhage known to be due to venous thrombosis
- •Risk/s of fluid retention associated with desmopressin judged clinically significant by the attending physician (for example patients with pulmonary oedema and/or cardiac failure)
- •Significant hypotension (systolic blood pressure <90mmHg)
- •Known drug-eluting coronary artery stent in previous three months
- •Allergy to desmopressin
- •Pregnant or breast-feeding
- •Life expectancy less than four hours, or planned for palliative care only
- •Glasgow coma scale less than 5
- •Participation in another concurrent drug trial
研究者
相似试验
已完成
2 期
Desmopressin for treatment of stroke patients on antiplatelet therapyHaemorrhagic strokeCirculatory SystemIntracerebral haemorrhageISRCTN67038373niversity of Nottingham54
已完成
2 期
Desmopressin for Reversal of Antiplatelet Drugs in Stroke Due to HaemorrhageStroke, AcuteNCT03696121University of Nottingham54
进行中（未招募）
1 期
Early reduction of antiplatelet therapy in patients with Acute Coronary Syndrome treated with stent implantation and at high risk of bleeding.MedDRA version: 20.0Level: PTClassification code: 10051592Term: Acute coronary syndrome Class: 100000004849Acute coronary syndromeCTIS2023-509868-20-00Azienda Ospedaliera Universitaria Gaetano Martino Messina200
招募中
1 期
Early reduction of antiplatelet therapy in patients with Acute Coronary Syndrome treated with stent implantation and at high risk of bleedingEUCTR2023-000029-10-ITAzienda Ospedaliera Universitaria Gaetano Martino Messina200
进行中（未招募）
不适用
Antiplatelet therapy in combination with Recombinant t-PA Thrombolysis in Ischemic Stroke - ARTISPatients with ischemic strokeMore specific patients with ischemic stroke treated with rt-PA thrombolysisEUCTR2006-006829-13-NLetherlands Heart Foundation1,000